New target for Alzheimer's drugs

UC Riverside biomedical scientists have identified a new link between a protein (beta-arrestin) and short-term memory that could open new doors for the therapeutic treatment of neurological disorders, particularly Alzheimer's disease. They show that if beta-arrestin is removed from neurons, short-term memory loss is prevented. But beta-arrestin is also required for normal learning/memory. The researchers argue that a fine balance needs to be established, one that could be achieved by pharmaceutical drugs in the future.

Read the whole article on Science Daily

More from Science Daily